Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This study aimed to explore perceived barriers to early diagnosis and management of oral cancer, as well as potential pathways for improvement in Latin America and the Caribbean (LAC).
Methods: This cross-sectional study used a self-administered online questionnaire created via the Research Electronic Data Capture platform. The survey was distributed to health professionals trained in Oral Medicine, Oral Pathology, Oral and Maxillofacial Surgery, and Dentists with clinical and academic expertise in oral potentially malignant disorder (OPMD) and oral cancer. Data obtained were systematically organized and analyzed descriptively using Microsoft Excel.
Results: Twenty-three professionals from 21 LAC countries participated. Major barriers included the limited implementation of OPMD and oral cancer control plans (17.4%), low compulsory reporting for OPMD (8.7%) and oral cancer (34.8%), unclear referral pathways for OPMD (34.8%) and oral cancer (43.5%), and a shortage of trained professionals (8.7%). Participants endorsed the utility of online education (100%) and telemedicine (91.3%).
Conclusion: The survey highlights major perceived barriers to early diagnosis and management of OPMD and oral cancer in LAC, as well as potential avenues for improvement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/odi.14903 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of an Oral Health Management Program During Pregnancy: A Randomized Controlled Trial.
Oral Dis
September 2025
Stomatology Hospital, School of Stomatology, Zhejiang, University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, Zhejiang, China.
Objective: To evaluate the effects of a Health Belief Model-based oral health management program on self-efficacy, oral health behaviors, and three periodontal clinical indicators among pregnant women.
Study Design: A randomized controlled trial was conducted with 65 participants randomly allocated to the intervention (n = 39) and control (n = 26) groups. The intervention included one face-to-face education, three video calls, two online lectures, and regular follow-up supervision in 1 month, while the control group received one face-to-face education.
Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology.
Clin Transl Oncol
September 2025
Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman, University, P.O.Box 84428, 11671, Riyadh, Saudi Arabia.
Esophageal cancer (EC) is one of the most serious health issues around the world, ranking seventh among the most lethal types of cancer and eleventh among the most common types of cancer worldwide. Traditional therapies-such as surgery, chemotherapy, and radiation therapy-often yield limited success, especially in the advanced stages of EC, prompting the pursuit of novel and more effective treatment strategies. Immunotherapy has emerged as a promising option; nonetheless, its clinical success is hindered by variable patient responses.
View Article and Find Full Text PDFThe effect of oral belzutifan on retinal hemangioblastomas in von Hippel-Lindau syndrome.
Can J Ophthalmol
September 2025
University of British Columbia, Department of Ophthalmology and Visual Sciences, Vancouver, BC, Canada.
Objective: To assess the effect of belzutifan, a first-in-class oral hypoxia-inducible factor 2α inhibitor, on retinal hemangioblastoma (RH) outcomes.
Subjects/methods: This is a single-centre retrospective cohort study of patients with confirmed von Hippel-Lindau syndrome (VHLS) and RH. Subjects were taking oral belzutifan for renal cell carcinoma, central nervous system hemangioblastoma, or pancreatic neuroendocrine tumours.
Prospective Evaluation of Patient Priorities in HPV-Driven Oropharyngeal Cancer Using the Chicago Priorities Scale: Considerations for Future Clinical Trial Design.
Int J Radiat Oncol Biol Phys
September 2025
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Nursing, Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne, Melbourne,
Purpose: This study examined head and neck cancer treatment outcome priorities in patients with human papillomavirus-associated oropharyngeal cancer (HPVOPC) before and 12 months (12m) after (chemo)radiotherapy ([C]RT).
Methods And Materials: Eligible patients were diagnosed with HPVOPC suitable for curative-intent primary [C]RT. Study data included responses to a modified version of the Chicago Priorities Scale (CPS-modified) and select items from the MDASI Head and Neck Cancer Module (MDASI-HN).
Microbiome unlocks cancer immunotherapeutic potential: state of the art and future.
Semin Cancer Biol
September 2025
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430079, China; Department of Oral & Maxillofacial - Head Neck Oncolo
Immunotherapy has overturned the traditional perception of cancer treatment and brought new vitality to the field of oncology, but it still has unresolved problems such as a low response rate and severe side effects. The microbiome has been found to be involved in tumorigenesis, progression, metastasis and immunity modulation. Especially in immunity, the microbiome plays a key role through delicate mechanisms that regulate the immune response not only from the whole body to the local tumor microenvironment but also from innate to adaptive immunity.
View Article and Find Full Text PDF